BR112022022608A2 - Compostos como inibidores de bcl-2 - Google Patents

Compostos como inibidores de bcl-2

Info

Publication number
BR112022022608A2
BR112022022608A2 BR112022022608A BR112022022608A BR112022022608A2 BR 112022022608 A2 BR112022022608 A2 BR 112022022608A2 BR 112022022608 A BR112022022608 A BR 112022022608A BR 112022022608 A BR112022022608 A BR 112022022608A BR 112022022608 A2 BR112022022608 A2 BR 112022022608A2
Authority
BR
Brazil
Prior art keywords
inhibitors
bcl
compounds
compounded
methods
Prior art date
Application number
BR112022022608A
Other languages
English (en)
Inventor
Zhang Weipeng
Liu Hongbin
Tan Rui
Li Zhifu
Rong Yue
Liu Qihong
Chen Zhifang
Chen Ling
Xu Hua
Zhou Zuwen
Yu Jinhua
Tan Haohan
Liu Bin
Wang Yunling
Yang Lijun
Jiang Lihua
He Chengxi
Zhao Xingdong
Lin Shu
Wang Weibo
Original Assignee
Fochon Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fochon Pharmaceuticals Ltd filed Critical Fochon Pharmaceuticals Ltd
Publication of BR112022022608A2 publication Critical patent/BR112022022608A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

COMPOSTO COMO INIBIDORES DE BCL-2. A presente invenção refere-se a certos inibidores de Bcl2, composições farmacêuticas dos mesmos e métodos de uso dos mesmos.
BR112022022608A 2020-05-08 2021-05-07 Compostos como inibidores de bcl-2 BR112022022608A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202063021816P 2020-05-08 2020-05-08
US202063115471P 2020-11-18 2020-11-18
US202163146601P 2021-02-06 2021-02-06
PCT/CN2021/092104 WO2021223736A1 (en) 2020-05-08 2021-05-07 Compounds as bcl-2 inhibitors

Publications (1)

Publication Number Publication Date
BR112022022608A2 true BR112022022608A2 (pt) 2023-05-02

Family

ID=78468646

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022022608A BR112022022608A2 (pt) 2020-05-08 2021-05-07 Compostos como inibidores de bcl-2

Country Status (11)

Country Link
US (1) US20230159527A1 (pt)
EP (1) EP4146649A1 (pt)
JP (1) JP2023525748A (pt)
KR (1) KR20230051125A (pt)
CN (1) CN115843297A (pt)
AU (1) AU2021268845A1 (pt)
BR (1) BR112022022608A2 (pt)
CA (1) CA3177906A1 (pt)
MX (1) MX2022014007A (pt)
TW (1) TW202200576A (pt)
WO (1) WO2021223736A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478520A (zh) * 2020-10-28 2022-05-13 杭州和正医药有限公司 Bcl-2蛋白凋亡诱导剂及应用
WO2022143602A1 (en) * 2020-12-28 2022-07-07 Ascentage Pharma (Suzhou) Co., Ltd. Methods of treating multiple sclerosis
CN117616023A (zh) * 2021-04-13 2024-02-27 爱新医药科技(香港)有限公司 Bcl-2或bcl-2/bcl-xl调节剂及其用途
WO2023088167A1 (en) * 2021-11-20 2023-05-25 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
WO2023104043A1 (zh) * 2021-12-06 2023-06-15 杭州和正医药有限公司 一种抗凋亡蛋白bcl-2抑制剂、药物组合物及其应用
WO2023231777A1 (en) * 2022-06-01 2023-12-07 Fochon Pharmaceuticals, Ltd. Compounds as bcl-2 inhibitors
WO2024032776A1 (en) * 2022-08-12 2024-02-15 Fochon Biosciences, Ltd. Compounds as bcl-2 inhibitors

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG192126A1 (en) * 2011-01-25 2013-09-30 Univ Michigan Bcl-2/bcl-xl inhibitors and therapeutic methods using the same
CN106749233B (zh) * 2016-11-24 2020-04-21 中山大学 一类磺酰胺衍生物及其应用
EP3788042A4 (en) * 2018-04-29 2022-01-26 BeiGene, Ltd. BCL-2 INHIBITORS
WO2020140005A2 (en) * 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
CN114929689A (zh) * 2019-10-28 2022-08-19 百济神州有限公司 Bcl-2抑制剂
WO2021110102A1 (en) * 2019-12-02 2021-06-10 Beigene, Ltd. Methods of cancer treatment using bcl-2 inhibitor

Also Published As

Publication number Publication date
MX2022014007A (es) 2023-02-09
KR20230051125A (ko) 2023-04-17
CA3177906A1 (en) 2021-11-11
JP2023525748A (ja) 2023-06-19
US20230159527A1 (en) 2023-05-25
TW202200576A (zh) 2022-01-01
AU2021268845A1 (en) 2023-01-05
CN115843297A (zh) 2023-03-24
EP4146649A1 (en) 2023-03-15
WO2021223736A1 (en) 2021-11-11

Similar Documents

Publication Publication Date Title
BR112022022608A2 (pt) Compostos como inibidores de bcl-2
BR112021024108A2 (pt) Inibidores de tead e usos dos mesmos
BR112021024224A2 (pt) Inibidores de tead e usos dos mesmos
BR112022011651A2 (pt) Degradadores de irak e usos dos mesmos
CO2022003782A2 (es) Inhibidores de kras g12d
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
BR112021019748A2 (pt) Degradadores de stat e usos dos mesmos
BR112018003343A2 (pt) compostos heteroarila como inibidores de irak e usos dos mesmos
BR112018003812A2 (pt) compostos de heteroarila como inibidores de irak e usos dos mesmos
EA201391127A1 (ru) C-17 и c-3 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
EA201691726A1 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
BR112015028171A8 (pt) Inibidores de acc e seu uso
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
UY37645A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112012017382A2 (pt) compostos inibidores de viroses flaviviridae, uso dos mesmos e composição farmacêutica
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
MX2020009234A (es) Compuestos de heteroarilo como inhibidores de cinasas asociadas con receptores de interleucina-1 (irak) tipo ii y usos de los mismos.
UY37646A (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
BR112017014970A2 (pt) macrociclos de piridazinona como inibidores de irak e usos dos mesmos
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
BR112022012410A2 (pt) Degradadores smarca e usos dos mesmos
SA519410093B1 (ar) مركبات بيريميدو بيريميدينون مفيدة كمثبطات دبليو إى إى-1 كيناز
BR112016002638A2 (pt) novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório
BR112022018678A2 (pt) Degradadores de mdm2 e usos dos mesmos
EA202091400A1 (ru) Производные пиррола в качестве ингибиторов асс